Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
The high prevalence of BRAF V600 gene mutation in the Russian Federation and the cost of treatment the metastatic melanoma (MM) with immuno-oncology and combined targeted drugs make it relevant to assess the clinical and economic feasibility of their use. Objective. Cost-effectiveness analysis (CEA)...
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artikel |
| Sprache: | Russian |
| Veröffentlicht: |
Izdatelstvo OKI
2018-07-01
|
| Schriftenreihe: | Качественная клиническая практика |
| Schlagworte: | |
| Online Zugang: | https://www.clinvest.ru/jour/article/view/403 |